NEUROONE MEDICAL TECHNOLOGIES Corp
For the period ended Sep 30, 2025. Filed Dec 17, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Dec 17, 2025
NMTC$0.89+0.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Operations
| Years ended September 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Product revenue | $9,097,692 | $3,453,003 |
| Cost of product revenue | 3,956,286 | 2,373,336 |
| Product gross profit | 5,141,406 | 1,079,667 |
| Collaborations revenue | 3,000,000 | — |
| Operating expenses: | ||
| Selling, general and administrative | 7,384,517 | 7,901,695 |
| Research and development | 4,983,362 | 5,065,181 |
| Total operating expenses | 12,367,879 | 12,966,876 |
| Loss from operations | (4,226,473) | (11,887,209) |
| Fair value change in warrant liability | 784,670 | (327,092) |
| Financing costs | (334,063) | (228,988) |
| Other income, net | 170,492 | 125,179 |
| Loss before income taxes | (3,605,374) | (12,318,110) |
| Provision for income taxes | — | — |
| Net loss | $(3,605,374) | $(12,318,110) |
| Net loss per share: | ||
| Basic and diluted | $(0.09) | $(0.46) |
| Number of shares used in per share calculations: | ||
| Basic and diluted | 40,152,873 | 26,762,392 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.